References
- Ytterberg SR, Bhatt DL, and Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022; 386(4): 316–326.
- Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79(11):1400–1413.
- Kremer JM, Bingham CO 3rd, and Cappelli LC, et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States–based rheumatoid arthritis registry. ACR Open Rheumatol. 2021; 3(3): 173–184.
- Taylor PC, Weinblatt ME, and Burmester GR, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019; 71(7): 1042–1055.
- Kim SC, Schneeweiss S, Liu J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res. 2013;65:1600–1607.
- Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme [published online ahead of print, 2020 Oct 28] [published correction appears in Ann Rheum Dis. 2021;80(5):e83]. Ann Rheum Dis. 2020;80(3):304–311.
- Choy E, Mcinnes I, Cush J, et al. Incidence and risk of venous thromboembolic events among patients with rheumatoid arthritis enrolled in the upadacitinib clinical trial program. Ann Rheum Dis. 2020;79:317–318.
- Winthrop KL, Tanaka Y, Takeuchi T, et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis. 2022;81(2):184–192.
- Takeuchi T, Tanaka Y, Tanaka S, et al. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: final results (32 months of mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Rheumatol Ther. 2021;8(1):425–442.
- Scott IC, Hider SL, Scott DL. Thromboembolism with Janus Kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk? Drug Saf. 2018;41(7):645–653.
- Yates M, Mootoo A, and Adas M, et al. Venous thromboembolism risk with JAK inhibitors: a meta-analysis. Arthritis Rheumatol. 2021; 73(5): 779–788.
- Cohen SB. JAK inhibitors and VTE risk: how concerned should we be? Nat Rev Rheumatol. 2021;17(3):133–134.
- Mori S, Ogata F, Tsunoda R. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Clin Rheumatol. 2021;40(11):4457–4471.
- Clarke B, Yates M, and Adas M, et al. The safety of JAK-1 inhibitors. Rheumatology. 2021; 60(Supplement_2): ii24–30.